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Cardiogenic and Aortogenic Brain Embolism
Eleni Doufekias, MD,* Alan Z. Segal, MD,† Jorge R. Kizer, MD, MSC, FACC*‡
New York, New York
Cardioaortic brain embolism is a potentially devastating condition that presents frequent diagnostic and thera-
peutic challenges. In this report, we review key aspects of the etiology, clinical presentation, diagnosis, progno-
sis, and treatment of cardiogenic and aortogenic stroke. Emphasis is on advances in diagnostic imaging capabil-
ities and on recent literature addressing secondary prevention for specific cardioembolic sources, upon which
diagnosis and prognosis primarily depend. While early evaluation with modern neuroimaging techniques offers
to enhance diagnostic accuracy, additional study is required to define optimal utilization. Appropriate imaging of
the heart and aorta is paramount to identifying potential sources of embolism. Secondary prevention for high-
risk embolic sources generally involves anticoagulation, but immediate initiation of anticoagulation is not rou-
tinely indicated. Medium-risk sources have more modest or undefined risks and little randomized comparative
evidence to guide management, but antiplatelet therapy is generally favored. One possible exception is patent
foramen ovale, for which high-risk features may warrant anticoagulation or mechanical closure. Definitive rec-
ommendations for this and other findings await completion of ongoing clinical trials. (J Am Coll Cardiol 2008;
51:1049–59) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.053c
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ltroke, which is almost 90% ischemic in nature, is a leading
ause of mortality and long-term disability worldwide (1).
hile the etiology of ischemic stroke is often found in the
ervicocranial vasculature, approximately 20% result from
igh-risk cardiac abnormalities (2,3). In another 30%, the
tiology cannot be established (2), but most “cryptogenic”
schemic strokes have embolic features (4), suggesting a
ossible cardioaortic origin (3).
Given the clinical importance of brain embolism arising
rom the heart and aorta, we prepared a narrative review
etailing optimal approaches to diagnosis and secondary
revention based on the latest available evidence and pub-
ished guidelines.
athophysiology
he brain, which receives 15% of cardiac output, is exquis-
tely sensitive to ischemia. Thus, material dislodged proxi-
ally to the great vessels often travels to the cervicocephalic
rteries, where impaction tends to manifest in stark clinical
erms. Most commonly, the embolic material is thrombus
5), whose propensity for spontaneous dissolution heightens
he risk of hemorrhagic conversion (6). While thromboem-
oli of central origin frequently occlude cerebral artery stems
r major branches (5), microemboli, such as air, fat, and
rom the Departments of *Medicine, †Neurology, and ‡Public Health, Weill
edical College of Cornell University, New York, New York. Dr. Kizer was
upported, in part, by Award K23 HL070854 from the National Heart, Lung, and
lood Institute.a
Manuscript received August 21, 2007; revised manuscript received November 12,
007, accepted November 14, 2007.holesterol crystals, may travel to smaller terminal branches,
eading to watershed infarction (7).
ymptoms and Signs
linical presentation is imperfect in differentiating cardio-
mbolic from noncardioembolic stroke (8). Cardiogenic
rain embolism presents characteristically with neurologic
eficits that are maximal at onset, reflecting sudden inter-
uption of blood flow (8). This contrasts with the stuttering
ourse attributed to atherothrombotic stroke (9). Yet be-
ause emboli can shift or fragment after initial impaction
3), presentation is nonabrupt in at least one-fifth of
ardioembolic strokes (8,9). Moreover, large-artery athero-
hrombosis causes not only hypoperfusion (7), but also
rtery-to-artery embolism (3). Accordingly, cardioembolic
eatures can occur in more than two-fifths of noncardioem-
olic strokes (9). Particular neurologic deficits favoring a
ardioembolic etiology have been identified, but have
uboptimal discriminatory capacity (10). While insensi-
ive, the most specific features for cardioembolism are
nfarcts in multiple territories and concurrent systemic
mbolism (8,10).
iagnosis
iagnosis of cardio/aortogenic infarction depends on cir-
umstantial evidence provided by detection of proximal
mboligenic findings (hereafter “cardiac sources of embo-
ism” [CSEs]) (Table 1) and supportive clinical, neuroim-
ging, or laboratory features.
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Cardiogenic and Aortogenic Stroke March 18, 2008:1049–59Neuroimaging. Magnetic reso-
nance imaging (MRI) affords su-
perior resolution than computed
tomography (CT), along with
the capacity to detect cerebral
ischemia within minutes of onset
(11). Cardiac emboli often oc-
clude large arteries or multiple
vascular territories (12), more
commonly affect certain vessels
(10), and frequently lead to hem-
orrhagic transformation (6). But
the utility of infarct features for
making a diagnosis of cardioem-
bolism is limited (10).
Noninvasive vascular imaging
has largely supplanted conven-
tional angiography, and can help
impugn a cardioaortic source, es-
pecially when used early (13).
The finding of a hyperdense ce-
rebral artery by noncontrast CT
(14), denoting thrombus (Fig. 1),
or its hyperintense counterpart
y MRI (15), confirms the diagnosis in the absence of
roximal arterial pathology. Early use of thin-section non-
ontrast CT in acute stroke outperforms conventional sec-
ioning, identifying intracranial thrombi in almost 90% of
ases (16). The presence of intracranial thrombus may also
e detected noninvasively with MRI angiography (17), CT
ngiography (18), or transcranial Doppler (19). Lately, MRI
as been applied to identify erythrocyte-rich thrombi, whose
etection provides direct support for cardioembolism (20).
roximal Sources of Embolism
Table 1 Proximal Sources of Embolism
High Risk Medium or Uncertain Risk
Atrial dysrhythmias
● Atrial fibrillation
● Sick sinus syndrome
● Atrial flutter
Interatrial septal abnormalities
● Patent foramen ovale
● Atrial septal defect*
● Atrial septal aneurysm
Left atrial thrombus
● Atrial dysrhythmias
● Mitral valve stenosis
Pulmonary arteriovenous malformation
Left ventricular thrombus
● Acute myocardial infarction
● Dilated cardiomyopathy
Spontaneous echo contrast (“smoke”)
Primary cardiac tumors
● Myxoma
● Papillary fibroelastoma
Mitral valve prolapse
Metastatic tumors to the heart* Valvular calcification
● Mitral annular calcification
● Aortic valve sclerosis/stenosis
Vegetations
● Infective
● Noninfective (marantic)
Valvular strands
Prosthetic cardiac valve
Complex aortic atheroma
Abbreviations
and Acronyms
AF  atrial fibrillation
ASA  atrial septal
aneurysm
CAA  complex aortic
atheroma
CSE  cardiac source of
embolism
CT  computed
tomography
INR  international
normalized ratio
LV  left
ventricle/ventricular
MRI  magnetic resonance
imaging
PFO  patent foramen
ovale
TEE  transesophageal
echocardiography
TTE  transthoracic
echocardiographyiNot discussed in this review.There are no published guidelines regarding the optimal
euroimaging approach, but contemporary techniques
romise substantial improvement in diagnostic accuracy.
ltimately, however, the diagnosis of cardio/aortogenic
troke rests with detection of the embolic source itself,
hich requires electrocardiographic monitoring and cardio-
ortic imaging.
chocardiography. In patients with clinically apparent
eart disease, the yield for CSEs of conventional transtho-
acic echocardiography (TTE) with agitated-saline injection
ay exceed 25% (21), but falls below 10% otherwise (13).
y contrast, the superior image resolution of transesopha-
eal echocardiography (TEE) permits identification of pos-
ible CSEs in more than 50% of patients without clinically
vert heart disease (21) or otherwise unexplained cerebro-
ascular events (22). In particular, TEE allows the diagnosis
f “complex” aortic atheroma (CAA), consisting of protrud-
ng, mobile, or ulcerated plaque (23). Newer techniques,
owever, have brought the diagnostic accuracy of TTE for
ight-to-left interatrial shunts closer to TEE (24–26).
econd-harmonic TTE can attain sensitivities of 62.5% to
0% compared with TEE (24,25).
There are scant data regarding the optimal echocardio-
raphic approach in suspected cardioembolic stroke. In a
tudy of unexplained stroke evaluated by both TTE and
EE, the latter technique yielded findings (patent foramen
vale [PFO], aortic thrombus) that prompted a change from
ntiplatelet to anticoagulant therapy in 30% of cases (27).
herapeutic decisions were based on clinical judgment,
owever, and randomized data supporting anticoagulant
herapy for these findings are lacking. Published guidelines
eflect the shortfall in available evidence and, while ac-
nowledging the superiority of TEE for detecting selected
SEs (Table 2) (28), do not make specific recommenda-
ions regarding imaging strategy (28,29).
Ongoing uncertainties notwithstanding, the higher yield
f TTE in patients with clinically overt heart disease
upports its use as the initial imaging technique in this
etting. Contrariwise, the higher prevalence of potential
SEs that are difficult to detect by TTE in younger patients
ith unexplained stroke, together with the potentially seri-
us consequences of occult pathology in this population,
akes TEE the modality of choice. Although transcranial
oppler with contrast injection can offer comparable diag-
ostic accuracy to TEE for right-to-left shunts (30), it
annot provide direct information on cardiac structure.
The case for cardioaortic embolism depends chiefly on
etection of a presumptive proximal culprit. Absent an
lternative explanation, identification of high-risk CSEs
akes a diagnosis of cardioembolic stroke likely, if not
efinite. Because the link of medium-risk CSEs to cerebral
nfarction is more modest or uncertain, their detection does
ot, in isolation, permit assignment of a cardioembolic
tiology. Adjunctive clinical and imaging findings, however,
uch as deep-vein thrombosis accompanying PFO, can
mplicate a medium-risk source as the likely offender. Yet
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March 18, 2008:1049–59 Cardiogenic and Aortogenic Strokedentification of even a high-risk source does not necessarily
onfirm cardioaortic embolism because CSEs often coexist
ith other potential stroke etiologies. Failure to detect a
otential CSE for a large-vessel infarct lacking another
xplanation leads to a designation of cryptogenic embolism.
rognosis and Treatment
ardioembolic stroke is associated with a worse outcome
han other stroke subtypes (31). Clinical trials of acute
ardioembolic stroke have failed to demonstrate the benefit
f acute intravenous anticoagulation, while showing greater
ymptomatic intracranial hemorrhage compared with anti-
latelet therapy (32). Current guidelines (2,33) do not
ecommend routine immediate anticoagulation, but favor
arly antiplatelet treatment for cardioembolic stroke.
Figure 1 Right Middle Cerebral Artery Thrombus
Computed tomography scan in a patient with atrial fibrillation, showing a hyperden
in the right middle cerebral artery consistent with thromboembolism (arrow). Figur
omparison of TTE and TEE for Detectionf Spec fic Cardioaortic Sources of Embolism
Table 2 Comparison of TTE and TEE for Detectionof Specific Cardioaortic Sources of Embolism
TTE* TEE†
Prosthetic valves Left atrial thrombus
Dilated cardiomyopathy Left atrial spontaneous echo contrast
Left ventricular aneurysm Aortic atheroma
Left ventricular thrombus Patent foramen ovale
Mitral valve prolapse Valvular strands
Vegetation
Atrial septal defect
Interatrial shunt‡
Atrial septal aneurysm
High-quality transthoracic echocardiography (TTE) is deemed sufficient if positive, such that
ransesophageal echocardiography (TEE) is not indicated in all patients. If TTE is negative, however,
EE can afford incremental diagnostic yield, especially for vegetations and atrial septal defect.
Transesophageal echocardiography is necessary for diagnosis. ‡Agitated-saline injection may(
eveal right-to-left interatrial shunt, but definitive diagnosis of patent foramen ovale, as compared
ith small atrial septal defect, requires TEE. Adapted from Cheitlin et al. (28).In acute as in chronic management, choice of an
ntithrombotic agent depends on the balance between
hromboembolic and hemorrhagic risk. Incidence of
emorrhagic transformation for cardioembolic stroke,
anging from petechiae to intrainfarct hematoma, aver-
ges 42% (6). Peak onset is 2 to 4 days, leading to the
roposition that, for atrial fibrillation (AF), anticoagula-
ion should be started 4 days post-stroke (34). Long-term
nticoagulation doubles the risk of intracranial hemor-
hage (from 0.3% to 0.6% annually) compared with
ntiplatelet treatment (35). Whereas acute hemorrhagic
isk correlates with infarct size (6), both acute and
hronic risks are determined by age, blood pressure, and
ntensity and stability of anticoagulation (35).
Although thromboembolic risk varies with emboligenic
ubstrate, existing literature addressing the risk of individual
SEs is predominantly observational and subject to bias
36). Nevertheless, available data permit useful categoriza-
ion of proximal sources based on their known propensity
or embolism (Table 1). Published treatment guidelines by
rofessional societies center on individual cardioembolic
ndings (Table 3), but the paucity of existing randomized
ata is an acknowledged limitation.
igh-risk sources. ATRIAL DYSRHYTHMIAS. Atrial fibril-
ation is the most common cause of cardioembolic stroke,
nd its close link to age augurs marked increases in preva-
ence in coming decades (37,38). Valvular AF is associated
ith higher stroke risk than nonvalvular AF (37). Throm-
oembolic risk is similar for paroxysmal and persistent
onvalvular AF, but is strongly determined by associated
ardiovascular risk factors (37). The severity and duration of
hese risk factors, through their effects on left ventricular
rations by Rob Flewell.
sity
e illustLV) function, influence the extent of left atrial enlargement
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Cardiogenic and Aortogenic Stroke March 18, 2008:1049–59ajor Professional Guidelines on Secondary Prevention for Selected Proximal Sources of Embolism
Table 3 Major Professional Guidelines on Secondary Prevention for Selected Proximal Sources of Embolism
Individual Disorders ACC/AHA*
American College of Chest
Physicians† American Stroke Association/AHA (1)*
AF/atrial flutter Chronic oral anticoagulant therapy to achieve
a target intensity INR of 2 to 3, unless
contraindicated (Class I, Level of Evidence: A);
aspirin in a dose of 325 mg daily as an
alternative in those with certain
contraindications to oral anticoagulation
(Class I, Level of Evidence: A) (46).
Anticoagulation with an oral
vitamin K antagonist, such
as warfarin (target INR 2.5;
range 2.0 to 3.0) (Grade 1A)
(45).
Anticoagulation with adjusted-dose warfarin
(target INR 2.5; range 2.0 to 3.0) (Class IA); if
unable to take oral anticoagulants, aspirin
325 mg/day (Class IA).
Rheumatic mitral valve
disease
Anticoagulation is indicated in patients with mitral
stenosis, even in sinus rhythm (63).
Long-term anticoagulation
therapy (target INR 2.5;
range 2.0 to 3.0) (Grade
1C) (62); if INR is
therapeutic, add aspirin 75
to 100 mg/day, or if unable
to take aspirin, dipyridamole
400 mg/day, or clopidogrel
(Grade 1C) (62).
Long-term warfarin therapy is reasonable, with a
target INR of 2.5 (range 2.0 to 3.0) (Class IIa,
Level of Evidence: C); antiplatelet agents
should not routinely be added to warfarin to
avoid the additional bleeding risk (Class III,
Level of Evidence: C).
In the case of recurrent embolism while on
warfarin therapy, adding aspirin (81 mg/day)
is suggested (Class IIa, Level of Evidence: C).
Acute myocardial
infarction
If cardiogenic source of embolism (AF, LV mural
thrombus, LV akinetic segment) present,
moderate intensity (INR 2 to 3) warfarin
anticoagulation (in addition to aspirin) of
variable duration depending on underlying
source. For LV thrombus or akinetic segment,
warfarin administered for 3 months, unless
follow-up echocardiography shows new,
enlarging, or mobile thrombus, wherein
anticoagulation is continued long term (Class I,
Level of Evidence: B); if no cardiogenic source
of embolism detected, in patients undergoing
stenting, clopidogrel 75 mg/day is added to
aspirin 75 to 162 mg/day for a minimum of 12
months. In patients not undergoing stenting,
aspirin/extended-release dipyridamole 25/200
mg plus aspirin 81 mg/day (60).
— When LV mural thrombus is identified, oral
anticoagulation is reasonable, aiming for an
INR of 2.0 to 3.0 for at least 3 months and
up to 1 year (Class IIa, Level of Evidence: B).
Aspirin should be used concurrently for ischemic
coronary artery disease during oral
anticoagulant therapy in doses up to 162
mg/day (Class IIa, Level of Evidence: A).
Dilated cardiomyopathy Absence of definitive trials cited, but
anticoagulation with warfarin “most justified” in
patients with heart failure and an embolic
event (61).
— Either warfarin (INR 2.0 to 3.0) or antiplatelet
therapy may be considered for prevention
of recurrent events (Class IIb, Level of
Evidence: C).
Valvular
prosthesis—mechanical
— If within INR range indicated for
specific prosthesis, addition
of aspirin 75 to 100 mg/day
and maintenance of INR at
target of 3.0 (range 2.5 to
3.5) (Grade 1C) (62).
For modern mechanical prosthetic heart valves,
oral anticoagulants with an INR target of 3.0
(range 2.5 to 3.5) (Class I, Level of Evidence:
B); when embolism occurs despite adequate
therapy with oral anticoagulants, aspirin 75 to
100 mg/day in addition to oral anticoagulants
and maintenance of the INR at a target of 3.0
(range 2.5 to 3.5) are reasonable (Class IIa,
Level of Evidence: B).
Valvular
prosthesis—biological
— Oral anticoagulation for 3 to 12
months (Grade 1C) (62).
Anticoagulation with warfarin (INR 2.0 to 3.0)
may be considered (Class IIb, Level of
Evidence: C).
Infective vegetations — — —
Noninfective (marantic)
vegetations
— Full-dose unfractionated
intravenous or subcutaneous
heparin (Grade 1C) (62).
—
Patent foramen ovale — — Antiplatelet therapy is reasonable to prevent a
recurrent event (Class IIa, Level of Evidence: B).
Insufficient data exist to make a recommendation
about closure in patients with a first stroke
and patent foramen ovale. Closure may be
considered for patients with recurrent
cryptogenic stroke despite optimal medical
therapy (Class IIb, Level of Evidence: C).
Alone — Recommend antiplatelet
therapy over no therapy
(Grade 1C) and suggest
antiplatelet therapy over
warfarin (Grade 2A) (2).
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March 18, 2008:1049–59 Cardiogenic and Aortogenic Strokend, consequently, the likelihood of AF-associated throm-
us formation (38). They also foster aortic and carotid
therosclerosis and small-vessel disease, which along with
tructural heart disease can themselves cause cerebral isch-
mia in AF patients (37). In this context, the interplay of
therosclerotic, inflammatory, and prothrombotic factors
as received attention (38).
Risk stratification can be accomplished with clinical
rediction instruments such as CHADS2, which assigns 1
oint each for Congestive heart failure, Hypertension, Age
75 years, and Diabetes, and 2 points for prior Stroke or
ontinued
Table 3 Continued
Individual Disorders ACC/AHA*
In combination with
other risk factors
(e.g.,
hypercoagulability,
atrial septal
aneurysm)
— Inad
a
o
(a
th
su
Intrapulmonary shunt —
Mitral valve prolapse For TIA: aspirin therapy (75 to 325 mg
daily) (Class I, Level of Evidence: C) (63).
For stroke: anticoagulation (INR 2.0 to
3.0) in setting of mitral regurgitation,
AF, or left atrial thrombus (Class I,
Level of Evidence: C), or in the
presence of mitral leaflet thickening
(5 mm) (Class IIa, Level of Evidence:
C); otherwise, aspirin therapy (Class
IIa, Level of Evidence: C) (63).
Antip
For u
a
d
For s
re
lo
(t
3
Mitral valve strands — Antip
Mitral annular calcification — If em
ca
a
ta
2
For r
d
w
a
re
co
Aortic valve disease/
calcific aortic
stenosis
— Sugg
vi
u
fo
(G
Aortic atherosclerosis — Antip
Complex aortic atheroma — Eithe
a
Oral
Cardiac tumors — Antic
American College of Cardiology (ACC)/American Heart Association (AHA)/American Stroke Asso
greement that a given procedure or treatment is beneficial, useful, and effective; Class II: conditi
f a procedure or treatment; Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy
here is evidence and/or general agreement that a procedure/treatment is not useful/effective an
rials or meta-analyses; Level of Evidence: B  data derived from a single randomized trial or
tandard-of-care. †American College of Chest Physicians grading of recommendations: 1A: strong
ecommendation; can apply to most patients in most circumstances. 1B: strong recommendation;
vidence is available. 2A: intermediate-strength recommendation; best action may differ dependi
epending on circumstances or patients’ or societal values. 2B: weak recommendation; alter
ecommendation; other alternatives may be equally reasonable.
AF  atrial fibrillation; INR  international normalized ratio; LV  left ventricular; TIA  transieransient ischemic attack (39). While identification of dense imoke or CAA by TEE also predicts AF-associated throm-
oembolic risk, its additive prognostic value to clinical
easures requires further investigation (23).
Atrial flutter and sick sinus syndrome are often associated
ith AF and structural heart disease (40–42). Thrombo-
mbolic risk is generally lower, if less well characterized,
han for AF, but is influenced by these relations
40,41,43,44).
Available guidelines (2,45,46) highlight the pre-
minence of prior stroke in amplifying thromboembolic risk
n AF. While the annual risk of thromboembolism is 0.5%
an College of Chest
Physicians† American Stroke Association/AHA (1)*
data available to make
mendation regarding
medical therapy
gulation or antiplatelet
versus endovascular/
closure (2).
Warfarin is reasonable for high-risk patients who have
other indications for oral anticoagulation such as
those with an underlying hypercoagulable state or
evidence of venous thrombosis (Class IIa, Level of
Evidence: C).
— —
therapy (Grade 1C) (2)
ined TIA: long-term
herapy (50 to 162 mg
rade 1A) (62).
ic embolism or
t TIAs despite aspirin,
vitamin K antagonist
NR 0.25; range 2.0 to
ade 2C) (62).
Antiplatelet therapy is reasonable (Class IIa, Level of
Evidence: C).
therapy (Grade 1C) (2) —
not documented to be
long-term oral
ulation therapy with a
R of 2.5—INR range
.0 (Grade 2C) (62).
d embolic events
oral anticoagulation, or
ultiple calcific emboli
gnized, valve
ent should be
red (62).
If embolism is not documented to be calcific,
antiplatelet therapy may be considered (Class IIb,
Level of Evidence: C).
In the presence of associated mitral regurgitation
(without AF), antiplatelet or warfarin therapy may
be considered (Class IIb, Level of Evidence: C).
For repeated embolic events despite antiplatelet or
warfarin therapy, or when multiple calcific emboli
are recognized, valve replacement surgery should
be considered.
ainst use of long-term
K antagonist therapy
ere is another indication
oagulation
2C) (62).
Antiplatelet therapy may be considered (Class IIb,
Level of Evidence: C).
therapy (Grade 1C) (2) —
anticoagulation or
let agents (Grade 2C) (2)
gulation (Grade 2C) (62)
—
tion not indicated (2) —
classification of recommendations: Class I: conditions for which there is evidence and/or general
which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy
IIb: usefulness/efficacy is less well established by evidence/opinion; Class III: conditions for which
me cases may be harmful. Level of Evidence: A  data derived from multiple randomized clinical
ndomized studies; Level of Evidence: C  only consensus opinion of experts, case studies, or
mendation; can apply to most patients in most circumstances without reservation. 1C: strong
apply to most patients. 1C: intermediate-strength recommendation; may change when stronger.
ircumstances or patients’ or societal values. 2C: weak recommendation; best action may differ
approaches likely to be better for some patients under some circumstances. 2C: very weak
emic attack.Americ
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nticoa
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Cardiogenic and Aortogenic Stroke March 18, 2008:1049–59hromboembolism (37). Given the magnitude of this risk
nd the strength of randomized data favoring warfarin over
spirin for thromboembolism prevention (47), guidelines
oncur in recommending adjusted-dose warfarin (interna-
ional normalized ratio [INR] 2.0 to 3.0) for patients with
erebral ischemia unless contraindications to anticoagula-
ion exist (Table 3) (1,2,45,46). (Strategies for rate and
hythm control are beyond the scope of this review, but
linical trials have not shown advantage to the latter [46].)
lthough less evidence is available, a similar approach is
dvocated for atrial flutter (46), and, in proportion to the
ikelihood of associated AF, warrants consideration for sick
inus syndrome.
EFT HEART THROMBUS. Since stasis is the principal deter-
inant of left atrial (appendage) thrombus formation,
hrombosis in this chamber (Fig. 2) is primarily observed
ith AF or mitral stenosis (48). Left atrial thrombus also
ccurs in sinus rhythm when myocardial or valvular disease
s present, but is exceedingly rare in their absence (48).
Myocardial infarction and dilated cardiomyopathy are most
requently associated with LV thrombus formation attributable
o stasis caused by regional or global myocardial dysfunction
49,50). Approximately 1% to 2.5% of patients with acute
yocardial infarction will suffer a stroke within 4 weeks,
ne-half in the first 5 days (51,52). Infarct location and severity
f systolic dysfunction determine the propensity for thrombo-
mbolism (53). Dyskinetic segments that remodel into aneu-
ysms remain chronic foci for potential thrombosis (54,55).
Dilated cardiomyopathy is also associated with LV
hrombus. Annual risk of embolization ranges approxi-
ately from 1.0% to 3.5% (50,56), paralleling the severity of
ystolic dysfunction (56–58), but climbs to 9% once stroke
as occurred (59).
Detection of intracavitary thrombus, especially when
obile, moves the benefit–risk calculus in favor of early
ost-stroke anticoagulation. In sinus rhythm, anticoagula-
ion should be instituted for at least 3 months, unless
ontraindicated, with demonstration of thrombus resolution
y echocardiography (1,60). Absent detectable thrombus,
Figure 2 LA Appendage Thrombus
Transesophageal echocardiogram in the longitudinal plane demonstrating echoden
(arrowheads) within the left atrial (LA) appendage (arrow), consistent with thrombpinion is divided regarding anticoagulation for secondary
troke prevention in acute myocardial infarction or dilated
ardiomyopathy (1,61), but it is recommended for rheu-
atic mitral stenosis (1,62,63).
ARDIAC TUMORS. Primary cardiac tumors are rare, account-
ng for a small minority of cerebrovascular events in reported
eries (21). Detachment of tumor fragments or superimposed
hrombi underlies embolic risk (64). Myxoma is the most
ommon, exceeding 50% of all benign cardiac tumors (64),
hile papillary fibroelastoma accounts for another 30% (65).
econdary stroke prevention entails surgical resection of myx-
ma or large, mobile fibroelastomas (2,64,65). This is usually
efinitive, but myxoma recurrences can occur (64).
ALVULAR VEGETATIONS. The incidence of ischemic stroke
ssociated with infective endocarditis is 15% to 20% (66),
ith the highest risk in the first 7 to 10 days after
resentation. Mitral valve involvement carries greater stroke
isk than aortic valve involvement (67). Embolic risk is also
ncreased by mobility, consistency, extent, and size (67–69).
arantic endocarditis, characterized by noninfective valvu-
ar vegetations, is seen in neoplastic or other debilitating
isorders and also confers a high risk of embolism (69,70).
Treatment must be directed at the underlying cause.
nfective endocarditis requires administration of systemic
ntibiotics and, if indicated, surgery (66). Noninfective
ndocarditis is treated with tumor-suppressive, antiretrovi-
al, or immunosuppressive therapy with systemic anticoag-
lation, preferably heparin based (62), as appropriate. Sterile
egetations, especially when large and mobile, make imme-
iate post-stroke anticoagulation compelling unless hemor-
hagic risk is excessive.
ROSTHETIC VALVES. Systemic embolization occurs as a
omplication of both bioprosthetic and mechanical heart
alves at 1% to 4% annually (62). Eighty percent of
linical thromboemboli associated with prosthetic valves
nvolve the brain. The absolute yearly risk of cerebral
mbolism is higher for prosthetic valves in the mitral (2%
o 3.5%) than aortic position (1% to 2%), and this risk is
mplified by AF (62).
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March 18, 2008:1049–59 Cardiogenic and Aortogenic StrokeHigh-intensity anticoagulation (INR 2.5 to 3.5) is
ecommended for modern mechanical prostheses when
erebral ischemia occurs, with addition of low-dose
spirin when the event occurs despite a therapeutic INR
1,62). Moderate-intensity anticoagulation can be con-
idered in the case of bioprostheses (1,62). Early initia-
ion/intensification of antithrombotic therapy should be
ntertained.
AA. Various studies in populations with cerebral isch-
mia have established a link between protruding aortic
theroma and systemic embolism (71), although an inde-
endent relation was not demonstrated in a community-
ased study with a modest number of outcomes (72). In a
rospective investigation of stroke patients age 60 years,
he presence of proximal aortic atheroma 4 mm in
hickness conferred a recurrence risk of 11.9 per 100
erson-years, compared with 3.5 per 100 person-years or
ess observed for atheroma4.0 mm (73). A TEE substudy
n AF, which defined CAA as 4 mm or containing
lceration or mobile components (23), demonstrated a
-fold greater risk of thromboembolism with than without
AA. Taken together, available data in patients with
erebral ischemia or AF show CAA to heighten thrombo-
mbolic risk, either directly or through associated cardio-
ascular disease (71).
Although CAA-associated thrombi would be expected to
e platelet-rich, some small-scale observational data suggest
hat secondary prevention with anticoagulation may be
uperior to antiplatelet therapy (71). Still, current guidelines
o not recommend routine anticoagulation (2). In the
resence of mobile atheroma, however, early systemic anti-
oagulation can be considered (Table 3) (2,62). The best
ntithrombotic strategy awaits completion of clinical trials,
ut aggressive lipid lowering and renin-angiotensin antag-
nism are indicated (74).
edium- or Uncertain-Risk Sources
FO. This fetal remnant constitutes a potential conduit for
ight-to-left shunting in 25% to 30% of adults (36). Many
Figure 3 Thrombus in Transit
Transesophageal echocardiographic view of the short axis of the heart, showing an
in the foramen ovale (arrow), consistent with thrombus in transit. The arrowhead75), but not all (76,77), studies have documented an
ssociation between PFO and ischemic stroke, particularly
n adults 55 years of age, in whom the prevalence rises to
0%. This relation is stronger for cryptogenic stroke, sug-
esting that PFO may be important in the pathogenesis of
erebral infarction. The putative mechanism, based on rare
nstances of thrombus “in transit” across the foramen in
atients with stroke (Fig. 3), is paradoxical embolism (78).
oint occurrence of venous thromboembolism and PFO
uffices for a circumstantial diagnosis of paradoxical embo-
ism (78), and autopsy series have identified paradoxical
mbolism as the culprit in as many as 4% of brain infarcts in
his manner (79). In such reports, however, cases with major
ulmonary embolism have predominated, leading to ascer-
ainment bias. By contrast, antemortem stroke studies
eldom uncover clinically overt pulmonary embolism or
onographic deep-vein thrombosis (36). This has prompted
onsideration of alternative mechanisms for the PFO-stroke
ssociation, including in situ thrombosis and atrial dys-
hythmias, but these are also rarely documented (36).
evertheless, a 1-mm thrombus sufficient to produce a
linical stroke can well elude detection by existing venous
maging modalities. Moreover, more extensive evaluation
ith conventional venography (80) and MRI venography
81) has documented frequent calf-vein and pelvic-vein
hrombosis in patients with unexplained systemic embolism
nd interatrial shunts.
Population estimates suggest that PFOs generally have
ow pathogenicity (36). Additional factors must, therefore,
ct to increase thromboembolic risk. Intrinsic PFO features
uch as anatomical degree of patency (82), magnitude of
icrobubble passage (83), septum-primum hypermobility
84), or presence of atrial septal aneurysm (ASA) (85) have
een reported to amplify risk. Moreover, an individual’s
ropensity to venous thrombosis, either from immobility or
ypercoagulable state, influences the associated risk of
aradoxical embolism (78).
SA. Defined as exaggerated excursion of the septum into
he atrial chambers, ASA occurs more frequently in patients
g echodensity with 2 distal extensions trapped
to the septum primum. Figure illustrations by Rob Flewell.oblon
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Cardiogenic and Aortogenic Stroke March 18, 2008:1049–59ith ischemic stroke than in the general population (7.9%
s. 2.2%) (86). The precise mechanism underlying this
ssociation is unclear. An interatrial shunt is present in 50%
o 90% of ASAs, suggesting paradoxical embolism as the
athophysiological basis (36). Additional potential mecha-
isms include in situ thrombosis (87) and associated atrial
ysrhythmias (88).
FO and ASA. There is no consensus regarding optimal
econdary stroke prevention for PFO (36). Treatment
ptions include antiplatelet or anticoagulant agents, and
ercutaneous or surgical closure. A substudy of patients with
oncardioembolic stroke randomized to aspirin versus war-
arin who underwent TEE found no difference in recurrent
troke or death, irrespective of PFO size or presence of ASA
89). In a subgroup with cryptogenic stroke, however,
arfarin reduced by one-half the risk of stroke or death, but
his analysis was underpowered (89). In a separate study of
ounger patients with cryptogenic stroke receiving aspirin,
rospective follow-up showed a similar 4-year risk of stroke
ecurrence for patients with isolated PFO and without PFO
85). For patients with both PFO and ASA, however, the
isk of recurrence was 4-fold greater than without either
bnormality (85). (Larger shunt size was associated with
SA, but it did not influence the risk of stroke recurrence.)
his observation, though at variance with findings in older
dults (89), suggests that aspirin affords insufficient protec-
ion for young cryptogenic stroke patients with combined
FO and ASA.
Patent foramen ovale closure has been traditionally ac-
omplished by open thoracotomy, but percutaneous closure
epresents an attractive alternative (36). Nevertheless, there
re no available randomized data on the relative merits of
ercutaneous (or surgical) closure and medical therapy (36).
linical trials addressing this question are ongoing.
Current guidelines conclude that available evidence pre-
ludes definitive treatment recommendations (1,2,36).
iven the high population prevalence of PFO, in the
bsence of high-risk clinical findings or septal characteris-
ics, it is difficult to establish the pathogenetic significance
r risk of PFO in the individual stroke patient. Accordingly,
ntiplatelet therapy is favored for PFO unless concurrent
enous thromboembolism or hypercoagulable state requir-
ng anticoagulation is detected (1,2). In the setting of
ryptogenic stroke and PFO with high-risk features—large
hunt (50 bubbles), ASA, antecedent Valsalva, multiple
nfarcts—especially in younger adults, long-term anticoag-
lation may be a preferred strategy. This is in keeping
ith the fibrin-rich composition of venous-source
hrombi (36). Patients interested in percutaneous closure
hould be encouraged to participate in clinical trials.
urgical closure is an alternative when anticoagulation is
ontraindicated. Optimal secondary prevention for iso-
ated ASA remains uncertain.
ntrapulmonary shunt. Pulmonary arteriovenous malfor-
ations, which constitute a conduit for paradoxical embo-ization, can be isolated or associated with liver disease or mereditary hemorrhagic telangiectasia (90). Among referrals
or endovascular occlusion, cerebral infarction was docu-
ented in 32% of patients with single, and 60% with
ultiple, malformations (91).
Transcatheter embolotherapy is favored for secondary stroke
revention for malformations 3 mm in diameter (91).
pontaneous echo contrast (“smoke”). This swirling
loud visible within cardiac chambers by echocardiography
eflects rouleaux formation from low flow, increased fibrin-
gen, or high hematocrit (92). Hence, it is common in
isorders such as AF and mitral stenosis, as well as pros-
hetic heart valves and severe ventricular dysfunction.
In AF, smoke typically occurs in the left atrial appendage,
here it correlates with reduced contractility (93). Dense
moke in the appendage is not only associated with throm-
us, but also predicts incidence of AF-related thrombo-
mbolism (23).
Because dense smoke represents a pre-thrombotic condi-
ion and is a marker of thromboembolic risk in AF, mitral
tenosis, or valvular replacement (94), systemic anticoagu-
ation may be contemplated in cryptogenic stroke patients in
inus rhythm with this finding.
itral valve prolapse. Early studies reported an associa-
ion between mitral valve prolapse and stroke, especially in
atients 45 years of age (95). Such studies applied echo-
ardiographic criteria that did not take into account the
addle-like shape of the mitral annulus. Subsequent revision
f these criteria yielded greater specificity, and several
tudies, albeit of limited power, have since failed to docu-
ent an association (96,97).
Guidelines do not recommend post-stroke anticoagula-
ion (1,2,63), except when leaflet thickening or mitral
egurgitation is present (63) (Table 3).
alvular calcification. Mitral annular calcification and
ortic valve sclerosis are associated with atherosclerotic
ascular disease (98,99). Prospective studies have shown
itral annular calcification to increase the risk of stroke
100), but the same has been documented for aortic valve
clerosis only when stenosis is present (101). While the
ssociation of mitral annular calcification with stroke reflects
ts status as a marker for atherosclerotic disease, several
eports attest to mitral annular calcification’s potential as a
irect source of calcific or thrombotic debris (98).
Recognizing the scant available data, published guidelines
1,62) suggest different general approaches to cerebral em-
olism not documented to be calcific in association with
itral annular calcification (Table 3), but urge consideration
f anticoagulation for accompanying mitral valve disease.
alvular strands. These mobile filaments represent endo-
helialized fibrin deposits arising from microabrasions of
alvular endothelium (102). Associations between valvular
xcrescences and stroke, ostensibly from embolization, have
een reported in cross-sectional studies (102), but failure of
ongitudinal studies to replicate the findings (103–105)akes a causal association suspect.
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March 18, 2008:1049–59 Cardiogenic and Aortogenic StrokeComparison of aspirin versus warfarin therapy in stroke
atients with strands showed no difference in outcome
105), and anticoagulation is not recommended (2).
onclusions
he diagnosis of cardio/aortogenic stroke relies on detection
f potential emboligenic sources in the absence of another
tiology of equal or greater plausibility. Early application of
odern neuroimaging techniques stands to bolster diagnos-
ic accuracy. Transesophageal echocardiography is the fa-
ored screening modality for CSE when clinical heart
isease is absent. Treatment for high-risk sources, whether
nticoagulation or surgery, is better established than for
edium- or uncertain-risk CSE, for which definitive rec-
mmendations are not possible. Additional investigation is
equired to optimize diagnostic and therapeutic approaches
or this serious condition.
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